Cryton Biosciences
Plug and Play · Cryton Biosciences is developing a first-in-class dual-action drug that restores mitochondrial function in immune AND cancer cells resulting in tumor death.
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
 Tradewind BioScienceShared: cancer cell, anti cancer, immuneActiveOther | Other | Active | YCW18 |
 Granza BioShared: immune cell, restore, cancerActiveOther | Other | Active | YCW24 |
 Modulari-TShared: cancer cell, immune cellActiveOther | Other | Active | YCW23 |
 Asher BioShared: immune cell, cancer, classActiveOther | Other | Active | YCS19 |
 Notable LabsShared: cancer cell, drugPublicOther | Other | Public | YCW15 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
 TareBioShared: immune cell, cancerActiveOther | Other | Active | YCS26 |
 Serinus BiosciencesShared: cancer cell, bioscienceActiveAI | AI | Active | YCS22 |
 CellChorusShared: immune cell, developingActiveAI | AI | Active | YCS21 |
 JWP GmbH Drug Eluting SolutionsShared: dual action, drug, developingNot statedOther | Other | Not stated | Plug and Play |
Also from Plug and Play
All of Plug and Play
Programs
| Program | Cohort | Source |
|---|---|---|
 Plug and Play | Not stated | Plug and Play Page |
About Cryton Biosciences
Cryton Biosciences is a lifetech company focused on addressing mitochondrial dysfunction, a critical factor in tumor growth and immune cell exhaustion. The company is developing a first-in-class dual-action drug that restores mitochondrial function in both immune and cancer cells, leading to immunogenic tumor death. This approach rewires tumor metabolism to induce stress and cell death while reversing immune exhaustion to enhance anti-cancer activity. The lead drug candidate, CB-101, has demonstrated robust anti-tumor efficacy in preclinical models of colorectal cancer and melanoma, including durable complete responses and enhanced effects when combined with standard chemotherapy. A patient selection strategy has been defined to target populations with high unmet medical needs. Cryton Biosciences has advanced a portfolio of optimized compounds and secured intellectual property protection for its lead chemical series. The company’s innovative dual-action mechanism represents a significant advancement in cancer therapeutics by simultaneously targeting tumor cells and revitalizing immune responses.
- Category
- Other
- Location
- United States
- Checked
- 3h ago
Cryton Biosciences: questions
Which accelerators did Cryton Biosciences go through?
Cryton Biosciences is listed by Plug and Play.
Where is Cryton Biosciences based?
Cryton Biosciences lists United States as its location on Plug and Play's page.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.